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Abstract
Autophagy, a degradation mechanism conserved among eukaryotes, plays an 
important role in cellular homeostasis by maintaining nutrients and energy balance. 
It is not surprising that autophagy has been associated with various pathological 
conditions such as neurodegeneration, aging, infection, and cancer. Its roles in can-
cer are complex and context-dependent. In this chapter, we will give an overview 
of regulation of autophagy with an emphasis in cancer and summarize the recent 
efforts in developing cancer therapeutics targeting autophagy.
Keywords: autophagy, autophagic cell death (ACD), autophagy-related genes (ATGs), 
signaling transduction pathway, antitumor drugs
1. Introduction
Autophagy derives from the Greek word “auto” and “phagein,” auto means “self,” 
and phagein means “eating,” so autophagy refers to a “self-eating” physiological 
phenomenon.
The concept was first proposed in the 1960s, when de Duve observed that 
intracellular components are encased in membranes to form cystic structures 
and transported to a small compartment, the lysosome, which is responsible 
for recycling to degrade these ingredients [1]. Further studies show cell com-
ponents, even organelles, are transported to the lysosome for degradation by 
cytoplasmic vesicles. Thus, the term autophagy was used for the first time 
to describe this process. But not until the early 1990s, the seminal work by 
Yoshinori Ohsumi on Saccharomyces cerevisiae resolved its molecular mechanism 
[2]. Now it is well-known that autophagy is the mechanism which maintains 
cellular homeostasis; damaged organelles or misfolded proteins are digested 
in lysosomes through autophagy for cellular energy recycling. However, 
autophagy is involved in the occurrence of cancer, neurodegenerative diseases, 
aging, and infection under pathological status. In this chapter, we focus on the 
formation and biological function of autophagy in cancer and discuss the appli-
cation of antitumor drugs that target autophagy-related molecules or regulate 
autophagic activities.
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2. Molecular mechanisms and biological functions of autophagy
2.1 Molecular mechanisms of autophagy
Autophagy is a lysosomal-mediated self-degradation process of intracellular 
components. Under normal physiological conditions, autophagy degrades damaged 
organelles and nonfunctional proteins in cells to provide energy and nutrients to 
maintain intracellular homeostasis. However, autophagy may be induced to partici-
pate in disease processes during fasting, drug interactions, nutritional deficiencies, 
hypoxia, or other stress reactions. Autophagy is divided into three stages: initiation, 
phagophore membrane formation and extension, and maturation. When the cellular 
sensation is subjected to external pressure, the signal-transduction molecules are 
activated, which regulates autophagy-related genes (ATGs) and promotes autophagy. 
The molecular mechanisms of the autophagy process are summarized in Figure 1 [3].
The energy receptor, AMP-activated protein kinase (AMPK), is activated to 
rapidly induce the upregulation of autophagy levels when cells are under nutrient 
and energy deficiency, protein accumulation, and stress. Autophagy induction is 
mainly achieved by the interaction between the Unc-51 like autophagy activat-
ing kinase 1 (ULK1) complex (including Atg1/ULK1, Atg17/FIP200, and Atg13) 
and mammalian target of rapamycin complex 1 (mTORC1) [4]. First, mTORC1 
is activated when cellular energy is sufficient, which then phosphorylates ULK1 
and Atg13 to inhibit autophagy. In contrast, mTORC1 activity is inhibited when 
cellular energy is deficient, and the resultant dephosphorylated Atg13 forms a 
complex with ULK1 and interacts with FIP200 to initiate autophagy [5]. The 
initiation of autophagy is closely related to the Class III PI3K (Vps34)-Atg6/Beclin1 
complex [6, 7]. The Beclin1-PI3K complex recruits Atg12-Atg5 and Atg16L multim-
ers and Atg8/microtubule-associated protein light chain 3 (LC3), which promotes 
the stretching and extension of autophagosome membranes [8]. The expansion of 
autophagosomes mainly depends on two ubiquitin-like conjugation systems: Atg12 
Figure 1. 
Schematic diagram of the molecular mechanisms of autophagy.
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binding and LC3-modification processes [9]. Atg12 binding is a ubiquitin-like 
process that requires the participation of ubiquitin-activating enzymes, E1 and 
E2. Atg12 is firstly activated by Atg7 (E1-like enzyme) and is then transported to 
Atg5 through Atg10 (E2-like enzyme), which subsequently binds to Atg16 to form 
a multibody complex and participates in the expansion of the autophagosome 
[10–12]. The LC3-modification process also requires the participation of ubiquitin-
activating enzymes, E1 and E2. After the formation of the LC3 precursor, it is 
processed into cytosolic soluble LC3-I by Atg4 and is then covalently linked to 
phosphatidylethanolamine (PE) by Atg7 (E1-like enzyme) and Atg3 (E2-like 
enzyme) to form a fat-soluble LC3-II-PE that participates in the extension of the 
autophagosome membrane. LC3-II binds to the newly formed autophagosome 
membrane until the formation of the autolysosome. Therefore, LC3-II is often 
used as a marker for autophagy [11, 13]. After formation, autophagosomes fuse 
with lysosomes through the microtubule cytoskeleton under the action of the 
endosomal-sorting complex required for transport (ESCRT), as well as through 
monomeric GTPase (RabS), to form autolysosomes. The autophagy-receptor 
protein, P62/SQSTM1, recognizes and binds to autophagy-substrate proteins by 
binding to the ubiquitin-associated (UBA) domain, either dependently or inde-
pendently. P62/SQSTM1 also anchors to the autophagosome membrane through 
the LC3/Atg8 interaction region (LIR); ultimately fusion between autophagosomes 
and lysosomes leads to P62/SQSTM1 entering into autolysosomes, together with 
the corresponding substrates and their degradation [14].
In addition to the direct involvement of the Atg gene in autophagy, some 
important signaling pathways also regulate autophagy. Among these pathways, 
the PI3k/Akt/mTOR pathway is a classical signal-transduction pathway associated 
with autophagy. Under nutrient-rich conditions, PI3k/Akt signaling activates the 
downstream mammalian target of rapamycin (mTOR) to form the mTOR complex 
consisting of ULK1/2, mATG13, FIP200, and Atg101. Once the mTOR complex is 
formed, phosphorylation of ULK1 and Atg13 results in ULK1 inactivation, which 
suppresses autophagy. In the absence of nutrients, the LKB/AMPK pathway is 
activated, and the binding of mTORC1 to ULK is blocked, thereby suppressing 
mTOR activity. Subsequently, ULK1 phosphorylates Atg13 and FIP200 to form 
autophagosomes, ultimately inducing autophagy [15]. The AMPK pathway is a 
cellular energy sensor, and it regulates the occurrence of autophagy. In the absence 
of nutrients, AMPK senses the changes in AMP levels and is activated, thereby 
phosphorylating tuberous sclerosis 2 (TSC2) and aggravating the inhibition of Rheb 
GTPase by TSC1/2, which ultimately inhibits mTOR activity and induces autoph-
agy. In addition, AMPK activates ULK1 through phosphorylation, thereby promot-
ing autophagy. Under nutrient-rich conditions, mTOR phosphorylates ULK1 to 
prevent AMPK from activating ULK1, which ultimately suppresses ULK1 activity 
and thereby inhibits autophagy [16]. The Hedgehog (Hh) signaling pathway also 
regulates autophagy. After Sonic hedgehog (SHh) in the Hh signaling pathway 
senses signaling stimulation, it transfers and binds to PATCHED-1 (PTCH) recep-
tor, thereby releasing inhibition of the G-protein-coupled receptor (GPCR)-like 
protein Smoothened (Smo). The activation of Smo ultimately leads to the activation 
of the downstream Gli transcription factor. Gli has three homologues, of which Gli1 
is involved in autophagy and inhibition of Gli1 induces autophagy. However, the 
mechanism by which Gli1 induces autophagy has not been well clarified [17, 18].
2.2 Autophagic cell death (ACD)
Programmed cell death is an orderly process, and, once this process is initiated, 
it proceeds automatically. Programmed cell death can be classified into at least three 
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types: type I (apoptosis), type II (ACD), and type III (necrosis or lysosomal death). 
Type I programmed cell death is accompanied with typical morphological changes 
of the cells—such as cell shrinkage, chromatin condensation, and apoptotic-body 
formation—following the initiation of apoptosis (Figure 2a). The morphological 
features of cells undergoing type II programmed cell death are not as obvious, and 
only autophagic vacuoles can be observed under electron microscopy (Figure 2b). 
Necrosis is a form of cell death characterized by organelle swelling, cytoplasmic-
membrane rupture, and leakage of cellular contents (Figure 2c). Therefore, ACD 
should be defined according to the following three features: (1) apoptosis is not 
triggered; (2) there is an increase in autophagic flux before or during cell death, 
rather than a mere elevation in autophagy marker; and (3) application of pharma-
ceutical inhibitor, like 3-MA, chloroquine, etc., or small interfering RNA (siRNA) 
against autophagy-related genes (Beclin1 or Atg5) inhibits cell death [19–21]. In 
short, ACD is a type of cell death caused by autophagy. Autophagy may also be 
involved in other types of cell death. Therefore, it is necessary to distinguish the dif-
ference between cell death that occurs with autophagy and cell death that is caused 
by autophagy. If inhibition of autophagy only changes cell morphologies but not the 
fate of cell death, then the death in question is cell death with autophagy. If inhibi-
tion of autophagy leads to alleviation or inhibition of cell death, then the death in 
question is cell death by autophagy [22].
The discovery of ACD has provided new ideas and strategies for anticancer 
therapy. It is well-known that autophagy plays a role as a “double-edged sword” in 
tumorigenesis (i.e., as a promoter and a suppressor of tumors). In terms of promot-
ing tumorigenesis, autophagy is a protective mechanism that protects tumor cells 
from being killed. However, ACD breaks the protective mechanism of autophagy. 
Drug and hypoxia-mediated ACD converts the autophagy that originally benefits 
tumor-cell survival to become harmful to tumor cells and inhibits tumor-cell prolif-
eration. In addition, there is a relationship between ACD and apoptosis, and autoph-
agy has been considered to be essential for the occurrence of apoptosis. Autophagy 
usually occurs before apoptosis, with apoptosis being initiated after autophagy, 
which leads to accelerated cell death. Some researchers believe that the occurrence 
of autophagy inhibits apoptosis and, thus, protects tumor cells. In addition, apop-
tosis can coexist with autophagy to collectively promote cell death [23]. Therefore, 
regardless of the single role of ACD or the combined effect of ACD and apoptosis, 
the above studies provide an important theoretical basis for the development of 
antitumor drugs. In fact, many antitumor drugs, either newly developed ones or old 
drugs with a new target, share the same mechanism in anticancer therapy by target-
ing programmed cell death.
Since the discovery of autophagy, especially its role in tumorigenesis and tumor 
development, the use of autophagy to regulate the programmed cell death of tumor 
cells has become a useful tool for anticancer therapy. Drug-induced ACD is also a 
Figure 2. 
Types of programmed cell death. a) apoptosis, b) autophagy and c) necrosis [22].
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primary mechanism for antitumor drugs. Therefore, autophagy has been widely 
studied as a drug target in antitumor research. First, this new research strategy of 
old drugs provides ideas for autophagy-targeted drug discovery. Some repurposing 
drugs—such as the antimalarial drug chloroquine, the antifungal drug bafilomy-
cin A1, and the immunosuppressant rapamycin—had not had their autophagy 
functions revealed when they were discovered. However, subsequent studies have 
revealed their other functions, which do not only induce autophagy but also inhibit 
tumor-cell proliferation through regulating autophagic activity. These old drugs are 
good candidates for being repurposed into antitumor drugs. Additionally, in the 
past few years with the development of omics technologies, a number of small-
molecule compounds targeting autophagy molecules or autophagy pathways have 
been discovered by high-throughput screening methods. These drugs also inhibit 
tumor-cell proliferation through the ACD pathway. The following section sum-
marizes drugs that control tumor proliferation by regulating autophagy activity in 
cancer stem cells (CSCs) and tumor cells, as well as their mechanisms of action.
3. Antitumor drugs that regulate autophagy to target cancer stem cells
Cancer stem cells (CSCs) are a type of cell with stem cell characteristics in 
tumors that exhibit strong self-renewal and proliferative ability and play an 
important role in tumor survival, proliferation, metastasis, and recurrence. Taken 
together, CSCs maintain the vitality of tumor-cell populations through self-renewal 
and infinite proliferation [24]. CSCs in tumor tissues in microenvironments 
with insufficient nutrients increase the recycling of intracellular substances by 
autophagy to continuously survive. Apoptosis, proliferation, and differentiation of 
CSCs are regulated by many factors, and autophagy and its signaling pathways play 
an important role in the apoptosis and differentiation of CSCs [25, 26]. A previous 
study has shown that the autophagy activity regulated by autophagy-related genes 
or autophagy pathways promotes the survival of CSCs. High Beclin1 expression 
promotes the survival and tumorigenicity of breast CSCs [27]. Chloroquine inhibits 
autophagy via the Janus kinase 2 (JAK2) and Hh pathways and kills breast and pan-
creatic CSCs [28, 29]. Nevertheless, another study has shown that autophagy also 
promotes the death of CSCs. CSCs from malignant gliomas cause cell death due to 
the accumulation of autophagy-related proteins and autophagosomes [30]. In addi-
tion, CSCs adapt to the changes of the microenvironment simultaneously through 
autophagy, and a large number of autophagosomes are found in damaged blood 
vessels and hypoxic parts of tumors. Autophagy induced by hypoxia-inducible fac-
tor (HIF) promotes metastasis of CD133+ pancreatic CSCs. Inhibition of autophagy 
reduces the viabilities of pancreatic cancer cells with stem cell characteristics and 
CD133+ liver CSCs under oxygen/nutrition deprivation [31]. Multi-regulation of 
autophagy on CSCs has prompted researchers to explore the feasibility of autophagy 
as a drug target for anticancer therapy. Numerous studies have demonstrated that 
some chemical synthetic drugs or natural extracts have a clear therapeutic effect on 
CSCs through regulating autophagy activity and may be used as novel antitumor 
treatments.
Small-molecule compounds induce programmed cell death in tumor cells 
through apoptosis and autophagy as their main antitumor mechanisms. After 
the concept of CSCs was proposed, researchers began to continuously explore 
small-molecule compounds and their effective targeting of CSCs. In 2009, Gupta 
et al. screened more than 16,000 compounds to discover that salinomycin has 
strong killing activity against breast CSCs and that the killing activity is >100-fold 
higher than that of paclitaxel [32]. Further studies have shown that salinomycin 
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has an inhibitory effect on a variety of CSCs. Salinomycin does not only induce 
apoptosis in CSCs but also inhibits DNA repair of CSCs. Interestingly, the prolifera-
tion of CSCs is inhibited by the increase or decrease of autophagic activity after 
the action of salinomycin [33]. On the one hand, after the action of salinomycin, 
the increase of reactive oxygen species (ROS) activates c-Jun N-terminal kinase 
(JNK) and AMPK signaling pathways to induce an increase of autophagy activity; 
on the other hand, salinomycin also affects the process of autophagosome and 
lysosome fusion and reduces the level of autophagic flux. These factors are the 
mechanisms by which salinomycin inhibits the proliferation of CSCs [34–36]. PI3k/
Akt/mTOR is a key pathway for autophagy regulation. When cells sense signs of 
starvation and hypoxia, they inhibit the activity of the PI3k/Akt/mTOR pathway 
and promote autophagy by phosphorylating Akt at amino-acid position 473 and 
mTOR at amino-acid position 2448. NVP-BEZ235 is a dual ATP-competitive 
PI3K and mTOR inhibitor, and its induced autophagy and apoptosis enhance the 
radiosensitivity of glioma stem cells [37]. Rottlerin, a small-molecule compound 
that acts as a protein kinase C-δ (PKC-δ) inhibitor, regulates the PI3k/Akt/mTOR 
pathway to activate autophagy. Rottlerin promotes the death of pancreatic CSCs 
through an endogenous apoptotic pathway after the activation of autophagy [38]. 
The same phenomenon is also observed in Rottlerin-treated prostate CSCs [39]. 
Nearly all malignant tumors have epigenetic abnormalities. Antitumor drugs 
targeting histone deacetylase (HDAC) are a primary focus in epigenetic research. 
Small-molecule inhibitors that target HDAC have a clear inhibitory effect on the 
proliferation of CSCs. Givinostat (ITF2357) and suberoylanilide hydroxamic acid 
(SAHA) are currently the most studied HDAC small-molecule inhibitors. Studies 
have shown that givinostat and SAHA can induce autophagy in lung and glioma 
CSCs, respectively, leading to cell death [40–42].
Autophagy is associated with drug resistance and metastasis of CSCs. Autophagy 
inhibitors or silencing of autophagy-related genes also affect the self-renewal and 
differentiation of CSCs or enhance the sensitivity of CSCs to chemotherapeutic 
drugs, thereby killing CSCs. The autophagy inhibitor, chloroquine, not only does 
inhibit autophagy activity of breast CSCs but also reduces the cell number and 
metastasis of breast CD44+/CD24−/low CSCs; this effect is damaging to the 
mitochondrial membrane structure, which leads to decreased cytochrome-c activity 
and increases oxidative stress. This process also leads to increased expression of the 
double-stranded DNA damage marker, γ-H2AX, which reduces the repair capacity 
of double-stranded DNA breaks, thereby inhibiting the proliferation of breast CSCs 
[43]. Drug resistance is a challenge for antitumor therapy. The small-molecule com-
pound, baicalein competitively binds to the GTPase SAR1B protein, guanosine tri-
phosphate, which is required for autophagy and inhibits autophagy activity, thereby 
selectively enhancing the sensitivity of mice liver CD133+ tumor-initiating stem 
cell-like cells (TICs) to mTORC1 inhibitors [44]. The autophagy inhibitor, quina-
crine, which can pass through the blood-brain barrier, also increases the sensitivity 
of glioblastoma stem-like cells (GSCs) to the chemotherapeutic drug, temozolomide 
(TMZ). The combination of quinacrine and TMZ promotes iron-dependent cell 
death (ferroptosis) in GSCs [45]. The bromodomain and extra-terminal domain 
(BET) inhibitor, JQ1, is ineffective for drug-resistant CD34+ CD8- leukemia stem 
cells (LSCs) and hardly induces apoptosis in drug-resistant LSCs. However, JQ1 
increases the expression of autophagy-related molecules, such as Beclin1 and 
LC3-II, through the AMPK-ULK1 pathway to promote autophagosome formation. 
The AMPK inhibitor, compound C, and AMPKα siRNA inhibit autophagy to further 
promote the apoptosis of drug-resistant CD34+CD8− LSCs [46].
In addition to small-molecule compounds, plant extracts also have an inhibi-
tory effect on CSCs. Curcumin is a chemical component extracted from the roots 
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of some plants in the Zingiberaceae and Araceae families. Among the numerous 
biological activities of curcumin, its antitumor activity has aroused the attention 
of tumor biologists. Studies have shown that curcumin has an inhibitory effect on 
liver and ovarian CSCs. Autophagy induced by curcumin treatment in the DCLK1+ 
colon CSCs inhibits cell proliferation via apoptosis [47]. Resveratrol not only does 
inhibit the proliferation of breast CSCs by autophagy [48] but also increases the 
trans-differentiation of colon CSCs into endothelial cells [49]. Bitter-melon whole 
Drugs Cancer stem cells Autophagy 
activity
Mechanism of 
autophagy regulation
References
Chloroquine Breast Autophagy 
inhibition
Jak2, DNMT1 [27, 42]
Pancreatic Autophagy 
unchanged
CXCR4 [28]
Salinomycin Breast Autophagy 
increasing
ROS [33]
Breast Autophagy 
inhibition
Apoptotic pathway [35]
Colon Autophagy 
induction
ROS [33]
NVP-BEZ235 Gliomas Autophagy 
induction
PI3k/Akt/mTOR [36]
Rettlerin Pancreatic Autophagy 
induction
Apoptotic pathway [37]
Prostate Autophagy 
induction
Apoptotic pathway [38]
Givinostat Lung Autophagy 
induction
HDAC [39]
Glioblastoma Autophagy 
inhibition
HDAC [40]
SAHA Glioblastoma Autophagy 
induction
HDAC [41]
Baicalein Mice liver tumor Autophagy 
inhibition
GTPase SAR1B protein [43]
Quinacrine Glioblastoma Autophagy 
inhibition
Lipid peroxides [44]
JQ1 Leukemia Autophagy 
induction
AMPK-ULK1 pathway [45]
Curcumin Colon Autophagy 
induction
DCLK1 [46]
Resveratrol Breast Autophagy 
induction
Wnt/β-catenin 
pathway
[47]
Colon adenocarcinoma Autophagy 
induction
Wnt pathway [48]
Bitter-melon 
fruit extracts
Colon and progenitor 
cells
Autophagy 
induction
AMPK pathway [49]
Abbreviations: Jak2: Janus kinase 2; DNMT1: DNA (cytosine-5)-methyltransferase 1; CXCR4: C-X-C chemokine 
receptor type 4; ROS: reactive oxygen species; HDAC: histone deacetylases; DCLK1: Doublecortin like kinase 1; ULK1: 
Unc-51 like autophagy activating kinase 1
Table 1. 
Antitumor drugs that target cancer stem cells by regulating autophagy.
Programmed Cell Death
8
fruit (BMW) and skin (BMSk) extracts significantly inhibit the proliferation 
and colonization of colon CSCs, and the BMW-treated colon CSCs also cause the 
upregulated expression of LC3-II, Beclin1, Atg7, and Atg12 to promote autophagy 
[50]. Table 1 summarizes the recent progress of mechanism, targets, and references 
of drugs in anticancer stem cells.
4. Antitumor drugs that regulate autophagy to target tumor cells
In the processes of tumorigenesis and tumor progression, autophagy has dual 
roles, and inhibition or promotion of autophagy is related to tumorigenesis. 
Some important signaling pathways—such as PI3K/Akt/mTOR, MAPK, JNK, 
and Hh pathways—do not only regulate tumor-cell growth and proliferation but 
also affect tumorigenesis by regulating autophagic activity. In addition, autoph-
agy-related molecules—such as Atg5, Atg7, and Beclin1—are associated with 
tumorigenesis. Therefore, research in recent years regarding autophagy-targeted 
antitumor drugs includes not only autophagy-related signaling pathways but also 
autophagy-related molecules. In this section, antitumor drugs, like compounds 
and nature extracts, which target the signaling pathway (Table 2) or autophagy-
related molecules (Table 3), are introduced, and their antitumor mechanisms are 
discussed.
Drugs Cancer cell Autophagy 
activity
Mechanism of autophagy 
regulation
References
Metformin Myeloma Autophagy 
induction
AMPK [50]
Rat liver carcinoma Autophagy 
inhibition
AMPK, p38/MAPK [51]
Cannabinoids Pancreatic cancer Autophagy 
induction
AMPK [52]
Safingol Colon carcinoma Autophagy 
induction
PI3K/Akt/mTOR [54]
Compound 6 Lung carcinoma Autophagy 
induction
PI3K/Akt/mTOR [55]
Cabazitaxel Lung carcinoma Autophagy 
induction
PI3K/Akt/mTOR [56]
Ophiopogon 
japonicus
Lung carcinoma Autophagic 
cell death
PI3K/Akt/mTOR [57]
Capsaicin Nasopharyngeal 
cancer cell
Autophagy 
induction
PI3K/Akt/mTOR [58]
NVP-BEZ235 T-cell acute 
lymphoblastic 
leukemia
Autophagy 
induction
PI3K/Akt/mTOR [59]
CYT-Rx20 Breast cancer Autophagy 
induction
MAPK [60]
AJ-5 Melanoma Autophagic 
cell death
MAPK [61]
Arsenic-trioxide Glioma Autophagic 
cell death
PI3K/Akt, ERK1/2 [62]
Fangchinoline Liver cancer Autophagic 
cell death
p53/sestrin2/AMPK [63]
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4.1 Autophagy pathways
4.1.1 Drugs that target AMPK pathway
AMPK is a metabolism and energy receptor of cells. The intracellular balance 
of energy and metabolism in tumor cells is often chaotic, leading to changes in 
AMPK activity to further cause activity changes of a series of downstream signal-
ing pathways, which affect the autophagy process. In addition to its therapeutic 
effect on type II diabetes, metformin has also been found to have a therapeutic 
effect on tumors. Wang et al. has shown that metformin targets the molecules of 
AMPK/mTORC1 and mTORC2 pathways in the tumor cells of multiple myeloma. 
Activation of AMPK signaling inhibits mTORC1 and mTORC2 to further induce 
autophagy and inhibit myeloma cell proliferation [51]. In contrast, metformin also 
inhibits autophagy and promotes apoptosis through AMPK and p38/MAPK signal-
ing pathways in the glucose-deprived H4IIE rat hepatocellular-carcinoma cell line 
[52]. Cannabinoids have a variety of biological activities, of which tumor inhibi-
tion has aroused attention from researchers. AMPK pathways activate autophagy 
after ROS-dependent activation in cannabinoid-treated pancreatic cancer cells, 
while ROS promotes GAPDH nuclear translation, leading to reduced glycolysis and 
NADH accumulation to block the Krebs cycle after blocking the respiratory-chain 
function. Simultaneously with the activation of the AMPK pathway, cannabinoids 
Drugs Cancer cell Autophagy 
activity
Mechanism of autophagy 
regulation
References
PEITC Liver cancer Autophagy 
induction
p53 [64]
Bafilomycin A1 B-cell acute 
lymphoblastic 
leukemia cell
Autophagy 
inhibition
Autophagosome-lysosome 
fusion inhibition
[66]
DQ661 Melanoma Autophagy 
inhibition
Autophagosome-lysosome 
fusion inhibition
[67]
lys05 Glioblastoma Autophagy 
inhibition
Autophagosome-lysosome 
fusion inhibition
[68]
Itraconazole Breast and liver 
cancer
Autophagic 
cell death
Hh [17]
GANT61 Breast and liver 
cancer
Autophagic 
cell death
Hh [17]
HhAntag Embryonal 
rhabdomyosarcoma
Autophagy 
induction
Hh [69]
Sonidegib Mantle cell 
lymphoma
Autophagy 
inhibition
Hh [70]
SAHA Colon and liver 
cancer
Autophagy 
induction
HDAC inhibitor [71]
Panobinostat Colon cancer Autophagy 
induction
HDAC inhibitor [72, 73]
MGCD0103 B-cell chronic 
lymphocytic 
leukemia
Autophagy 
inhibition
HDAC inhibitor [74]
Abbreviations: AMPK: 5' AMP-activated protein kinase; MAPK: mitogen-activated protein kinase; PEITC: phenethyl 
isothiocyanate; SAHA: Suberoylanilide hydroxamic acid; HDAC: histone deacetylases; Hh: Hedgehog
Table 2. 
Antitumor drugs that target cancer cells by regulating autophagy.
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also inhibit the Akt/c-Myc pathway, resulting in the reduction of pyruvate kinase 
isoform M2 (PKM2) activity, glycolysis, and glutamine uptake. Therefore, can-
nabinoids inhibit the proliferation of pancreatic cancer cells through autophagy and 
cellular-metabolic pathways regulated by the AMPK pathway [53].
4.1.2 Drugs that target PI3K/Akt/mTOR pathway
The PI3K/Akt/mTOR pathway is directly involved in tumor-cell proliferation, 
and small-molecule drugs or natural extracts act on the PI3K/Akt/mTOR path-
way to regulate tumor cell proliferation through autophagy. Specifically, 3-MA, 
LY294002, and wortmannin are classic inhibitors of the PI3K/Akt/mTOR pathway 
to suppress autophagy, which have killing effects on various tumor cells [54]. In 
addition, many compounds that regulate autophagy and inhibit tumor cells via the 
PI3K/Akt/mTOR pathway have been discovered in recent years. Protein kinase C 
and the sphingosine kinase inhibitor, Salingol, inhibit the phosphorylation level of 
key molecules of the PI3K/Akt/mTOR pathway—such as Akt, p70S6k, and rS6—to 
induce ACD in colon cancer cells [55]. A novel hybrid of the 3-benzyl coumarin 
seco-B-ring derivative and phenylsulfonylfuroxan (compound 6) reduces the phos-
phorylation levels of mTOR-S2448, Akt-S373, and the downstream p70s6K-S371 
and 4EBP1-pT45 proteins in a concentration-/time-dependent manner to induce 
autophagy and apoptosis of A549 cells [56]. The antiprostate-cancer drug, cabazi-
taxel, also inhibits proliferation of A549 cells through autophagy which is regulated 
by the PI3K/Akt/mTOR pathway [57]. Ophiopogon japonicus is a traditional medici-
nal plant, and its main components are flavonoids and steroidal saponins. A previ-
ous study has shown that O. japonicus inhibits PI3K/Akt/mTOR signaling to induce 
ACD in A549 lung cancer cells [58]. Similarly, the inhibitory effect of capsaicin in 
the nasopharyngeal carcinoma cell line, NPC-TW01, is also achieved by autophagy 
regulated by the PI3K/Akt/mTOR pathway [59]. Specifically, mTORC1 is a key sig-
naling molecule in the PI3K/Akt/mTOR pathway. Some small-molecule drugs, such 
as rapamycin and NVP-BEZ235, inhibit mTORC1 activity and induce autophagy 
and have a killing effect on T-cell acute lymphoblastic leukemia cells [60].
4.1.3 Drugs that target the MAPK pathway
The MAPK pathway plays an important role in the process of tumor-cell prolif-
eration, growth, apoptosis, and cell-to-cell functional synchronization. The MAPK 
family members, ERK, p38 MAPK, JNK, and ERK5 are also involved in the regula-
tion of autophagy. CYT-Rx20, a derivative of β-nitrostyrene, inhibits proliferation 
in the breast cancer cell lines, MDA-MB-231 and MCF-7 [61]. A new binuclear pal-
ladacycle complex, AJ-5, does not only induce apoptosis in melanoma cells but also 
inhibit Akt/mTOR activity and activate p38 and ERK1/2 MAPK signaling to induce 
ACD, with dual roles in apoptosis and ACD to inhibit the proliferation of melanoma 
cells [62]. Similar to AJ-5, arsenic-trioxide and ionizing-radiation combination 
treatment on glioma cells also inhibits Akt/mTOR activity and activates ERK1/2 
MAPK signaling to promote ACD [63].
4.1.4 Drugs that target the p53 pathway
p53 is a tumor-suppressor protein that regulates the expression of multiple 
genes involved in apoptosis, growth inhibition, and DNA repair. Studies have 
shown that the regulation of autophagy by p53 is bidirectional depending on its 
localization. Cytoplasmic p53 inhibits autophagy in a transcriptional-independent 
manner, while nuclear p53 enhances autophagy by transactivation target gene. 
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P53 in human hepatocellular-carcinoma cells treated with fangchinoline is trans-
ported from the cytoplasm to the nucleus through nuclear translocation and selec-
tively activates sestrin2 to initiate autophagy and promote ACD [64]. Numerous 
studies have shown that cruciferous-vegetable-derived phenethyl isothiocyanate 
(PEITC) reactivates the normal activity of mutant p53 molecules in tumor cells 
and has an antitumor effect. PEITC has growth-inhibitory activity on tumor cells 
expressing p53R175H and restores the wide-type conformation and transcriptional 
activity of p53. In addition, PEITC enables p53R175H tumor cells to be sensitive 
to proteasome and autophagy-mediated degradation processes. Analysis of the 
mechanism showed that PEITC activates the classical p53 downstream target gene, 
causing tumor cells to arrest in the S phase and G2/M phase of the cell cycle and to 
undergo apoptosis [65].
4.1.5 Drugs that target the autophagosome-lysosome fusion pathway
The fusion of autophagosomes and lysosomes forms autolysosomes, which 
degrade the encapsulated materials. The degradation activity can be evaluated 
by autophagic flux. A previous study has shown that antimalarial drugs—such as 
quinine, chloroquine, and its derivatives—block the fusion processes of autophago-
somes and lysosomes to reduce the autophagic flux and kill tumor cells by inhibiting 
Drugs Cancer cell Autophagy 
activity
Mechanism of 
autophagy regulation
Refs.
SBI-0206965 Lung cancer cell Autophagy 
inhibition
ULK1 inhibitor [75]
MRT67307 Mouse embryonic 
fibroblast
Autophagy 
inhibition
ULK1 inhibitor [76]
MRT68921 Mouse embryonic 
fibroblast
Autophagy 
inhibition
ULK1 inhibitor [76]
LYN-1604 Breast cancer cell Autophagy 
induction
ULK1 inhibitor [77]
SAR405 Renal tumor Autophagy 
inhibition
Vps34 inhibitor [78]
Spautin-1 Cervical cancer Autophagy 
inhibition
Vps34 inhibitor [80]
S130 Colon cancer Autophagy 
inhibition
Atg4B inhibitor [81]
NSC185058 Saos-2 osteosarcoma cell Autophagy 
inhibition
Atg4B inhibitor [82]
Obatoclax Lymphoblastic leukemia Autophagic cell 
death
Bcl-2 inhibitor [87]
ABT-737 Cervical cancer Autophagy 
induction
Bcl-2 inhibitor [86]
ABT-737 Colon cancer Autophagy 
inhibition
Bcl-2 inhibitor [87]
gossypol Glioma Autophagic cell 
death
Bcl-2 inhibitor [88, 
89]
Verteporfin Prostate cancer cell Autophagy 
inhibition
p62/SQSTM1 inhibitor [90]
Table 3. 
Small molecular inhibitors of autophagy-related molecules.
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autophagy activity [66]. Bafilomycin A1 is a vesicular H+-ATPase proton-pump 
inhibitor that inhibits autolysosome activity to promote tumor cell killing by 
inhibiting the activity of vacuolar V-ATPases [67]. In addition to the above drugs, 
studies in recent years have shown that some small-molecule drugs, such as lys05 
and DQ661, share similar antitumor mechanisms [68, 69].
4.1.6 Drugs that target the Hh pathway
The Hh pathway plays an important role in embryonic development and tis-
sue regeneration. Abnormal expression of SMO, PTCH, and Gli1 molecules in the 
Hh pathways is associated with tumorigenesis. The Gli1 small-molecule inhibitor, 
GANT61, does not only inhibit the proliferation of human hepatocellular-carci-
noma cells but also synergize with itraconazole to kill breast cancer cells through 
the ACD pathway [18]. HhAntag, a small-molecule inhibitor of downstream ele-
ment of Hh pathway, inhibits embryonal rhabdomyosarcoma (ERMS) proliferation 
through autophagy induction [70]. SMO antagonist, Sonidegib, selectively targets 
cell migration and adhesion of mantle cell lymphoma (MCL) and suppresses the 
proliferation of MCL via autophagy inhibition [71].
4.1.7 Drugs that target the epigenetic pathways
Epigenetic modification can regulate the occurrence of autophagy, includ-
ing histone acetylation and DNA methylation, which play an important role in 
regulating the biological function of autophagy. Inhibition of HDAC activity to 
induce cell death has been the research strategy of antitumor drugs. Development 
of small-molecule inhibitors targeting HDAC has become a primary focus in 
this field. The small-molecule inhibitor, SAHA, does not only induce a killing 
effect on CSCs but also promote colon cancer and liver cancer cell death by 
FoxO1-dependent autophagy [72]. Panobinostat (LBH589) induces autophagy in 
a tumor-suppressor death-associated protein kinase (DAPK)-dependent manner 
and inhibits colon cancer cell proliferation. The combination of panobinostat and 
sorafenib significantly improves the therapeutic outcomes of liver cancer treat-
ment [73, 74]. MGCD0103 not only induces apoptosis in B-cell chronic lym-
phocytic leukemia (CLL) but also inhibits tumor-cell protective autophagy and 
promotes CCL cell death through the activation of the PI3K/AKT/mTOR signaling 
molecules and caspase pathways [75].
4.2 Small molecular inhibitors of autophagy-related molecules
4.2.1 Atg1/ULK1
The autophagy-related gene, Atg1 homologue, ULK1, is an unc-51-like serine/thre-
onine kinase that plays an important role in initiating autophagy. When cells are under 
nutrient deficiency, hypoxia, and other stresses, the upstream molecules of ULK1, 
mTORC1, and AMPK are activated, and the phosphorylation of ULK1 and Atg13 
molecules regulates autophagy. In recent years, ULK1 has been a popular molecule in 
the research of autophagy-targeted drugs. ULK1 not only is a promoter of autophagy 
but is also an important kinase, which is more favorable for the study of small-mole-
cule inhibitors. The high-throughput screening of Egan et al. [76] has shown that the 
small-molecule compound, SBI-0206965, inhibits ULK1 activity through the mTOR 
pathway, leading to a decrease in autophagy and inhibition of A549 cell proliferation. 
Unlike SBI-0206965, MRT67307 and MRT68921 inhibit both ULK1 and ULK2 activi-
ties and block autophagy [77]. The small-molecule compound, LYN-1604, and ULK1 
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reactive proteins—ATF3, RAD21, and caspase 3—activate autophagy to inhibit the 
proliferation of MDA-MB-231 triple-negative breast cancer cells [78].
4.2.2 Vps34
Vps34 is a Class III phosphoinositide-3 kinase (PI3K-III), and its 3-phos-
phophosphatidylinositol (PI3P), which catalyzes the formation of the substrate 
phosphatidylinositol (PI), is necessary for autophagosome formation. The small-
molecule inhibitor, SAR405, inhibits the catalytic activity of PIK3C3/Vps34, blocks 
the transport of vesicles from late endosomes to lysosomes, and inhibits autophagy, 
which suppresses tumor-cell proliferation [79]. In addition, PIK-III and Vps34-IN1 
are also Vps34 inhibitors, which inhibit autophagy and have killing effects on tumor 
cells [80]. Spautin-1 is a potent and specific small-molecule inhibitor. It inhibits two 
ubiquitin-specific peptidases, USP10 and USP13, and promotes ubiquitination and 
degradation of the Vps34-PI3K complex, thereby inhibiting autophagy [81].
4.2.3 Atg4B
Atg4 is a key molecule in autophagy that cleaves the C-terminal arginine of 
Atg8/LC3 to expose the C-terminal glycine residue for covalent attachment to 
phosphatidylethanolamine (PE). This process induces Atg8/LC3-PE to be anchored 
to the membrane of autophagosomes to regulate autophagy. Fu et al. [82] identi-
fied a novel ATG4B small-molecule inhibitor, S130, through in silico screening 
and in vitro high-throughput screening system for fluorescence resonance-energy 
transfer and showed that S130 did not affect the autophagosome function and 
autophagosome fusion with lysosomes. Instead, S130 inhibited the delipidation 
process of LC3-PE and ultimately blocked autophagy. An antitumor study has 
shown that S130 effectively inhibits the growth of colon cancer cells, and nutrient 
deficiency further enhances the antitumor effect of S130; however, Atg4 overex-
pression partially counteracts the tumor-cell death process caused by S130. Similar 
to S130, NSC185058 is also a newly discovered small-molecule inhibitor that acts on 
the Atg4B target and inhibits autophagy after LC3B lipidation, leading to the death 
of the Saos-2 osteosarcoma cells [83].
4.2.4 B-cell lymphoma/leukemia-2 (Bcl-2)
Bcl-2 is an antiapoptotic protein containing multiple Bcl-2 homology (BH) 
domains. Under starvation conditions, activation of JNK1 phosphorylates Bcl-2 
protein and causes the separation between Bcl-2 and Beclin1, thereby inducing 
autophagy [84]. In addition, multiple Bcl-2 homology 3 (BH3) mimetics can disrupt 
the interaction of Bcl-2/xl with Beclin1 to induce autophagy by competing for the 
BH3 domains [7]. Obatoclax (GX15-070) is a pan-Bcl2 inhibitor that induces apop-
tosis in various tumor cells. It also induces ACD in acute lymphoblastic leukemia 
cells in an Atg-dependent manner [85]. ABT-737, as a BH analogue, binds to the BH3 
binding groove of Bcl-2 and Bcl-xl. A study by Maiuri et al. [86] has shown that the 
degree of polymerization of Beclin1, Bcl-2, and Bcl-xl is significantly reduced in 
ABT-737-treated cells, which enhances the autophagy level. However, ABT-737 also 
enhances the sensitivity of colon cancer cells to the chemotherapeutic drug, ixazo-
mib, through downregulation of Mcl-1 and autophagy inhibition [87]. Similarly, 
gossypol is a small-molecule inhibitor of Bcl-2. Under natural conditions, gossypol 
is a mixture of (+)-gossypol and (−)-gossypol, and compared with (+)-gossypol, 
(−)-gossypol has higher antitumor activity. Gossypol and (−)-gossypol induce 
autophagy by inhibiting the response of Beclin1 and Bcl-2 in different tumor cells. 
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They can inactivate cytoprotective autophagy to cause tumor cells to escape [88], 
promote pro-survival autophagy, and initiate ACD [89].
4.2.5 p62
p62, also known as SQSTM1 protein, plays an autophagy and apoptotic role 
in tumor cells. The LIR domain of four domains of the p62 protein is responsible 
for binding to the autophagy-receptor protein, Atg8/LC3, while the UBA domain 
can recruit ubiquitinated proteins to mediate autophagic degradation. Verteporfin 
is an inhibitor of p62 and has no effect on cell growth under normal conditions. 
However, verteporfin reduces the survival of MCF-7 cells during nutrient depriva-
tion. In vivo experiments have shown that verteporfin also inhibits tumor formation 
frequency of PC-3 prostate cancer cells in a xenograft model [90].
In addition to small-molecule drugs and natural extracts, some macromolecular-
antibody drugs and noncoding miRNAs (miR)—such as anti-EGFR monoclonal 
antibody panitumumab, anti-20 monoclonal antibody rituximab, miR-22, and 
miR-101—have been reported to inhibit tumors in recent years through regulating 
autophagy activity [91, 92]. Although the emergence of autophagy provides a new 
idea for the development of antitumor drugs, anticancer treatments still encounter 
many challenges. Screening for drugs that target autophagy activity in cells may be 
the solution to some of these problems in the future.
5. Conclusion
The molecular mechanism and biological function of autophagy are now basi-
cally clear, and Janus role of autophagy determines that it plays an important role in 
the antitumor process. Some compounds, plant extracts killing tumor cells through 
the regulation of autophagy activity, especially induced autophagic cell death has 
also become an important strategy against tumor. However, there are still many 
obstacles to overcome in order to develop autophagic drugs; for example, there is a 
lack of specific biomarkers to distinguish autophagic cell death from other types of 
cell death. There is also a need to clarify which type of autophagy, cytoprotective, 
or cytotoxic should be targeted. Moreover it is difficult but important to determine 
to what extent autophagy should be induced before the cells reach the point of no 
return and undergo autophagic cell death.
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